William Blair Comments on Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Research analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for shares of Upstream Bio in a note issued to investors on Thursday, November 7th. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.66) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($3.79) per share.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.83 million.

Several other equities analysts also recently commented on UPB. TD Cowen started coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Piper Sandler began coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $75.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price objective for the company.

Upstream Bio Stock Down 1.6 %

UPB opened at $26.38 on Monday. Upstream Bio has a 1-year low of $20.74 and a 1-year high of $29.46.

Insider Transactions at Upstream Bio

In other Upstream Bio news, Director Erez Chimovits bought 825,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares in the company, valued at $77,432,841. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Erez Chimovits bought 825,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the acquisition, the director now owns 4,554,873 shares in the company, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.